Literature DB >> 26431835

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Paola Guglielmelli1,2, Giada Rotunno3,4, Annalisa Pacilli5,6, Alessandro Maria Vannucchi7,8.   

Abstract

The molecular landscape of patients with myelofibrosis (MF) includes "phenotypic driver" and "subclonal" mutations. The three driver (JAK2, MPL and CALR)-mutated genes currently represent major diagnostic criteria, unlike subclonal mutations that are not specific for the disease and occur in other myeloid neoplasms. Recent data indicate that selected mutations deserve prognostic significance allowing to identify categories of patients with different survival and risk of leukemia. This review focuses on current knowledge regarding genotype-prognostic correlates in MF, however, with the understanding that this is a rapid moving field and no definite recommendations for the clinicians can be done yet.

Entities:  

Keywords:  ASXL1 mutations; CALR mutations; Essential thrombocythemia; Myelofibrosis; Polycythemia vera; Prognosis

Mesh：

Substances：

Year:  2015        PMID： 26431835     DOI： 10.1007/s11899-015-0285-y

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  65 in total

1.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Authors:  Haefaa Alchalby; Anita Badbaran; Tatjana Zabelina; Guido Kobbe; Joachim Hahn; Daniel Wolff; Martin Bornhäuser; Christian Thiede; Herrad Baurmann; Wolfgang Bethge; York Hildebrandt; Ulrike Bacher; Boris Fehse; Axel R Zander; Nicolaus Kröger
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

2.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

Authors:  P Guglielmelli; T L Lasho; G Rotunno; J Score; C Mannarelli; A Pancrazzi; F Biamonte; A Pardanani; K Zoi; A Reiter; A Duncombe; T Fanelli; D Pietra; E Rumi; C Finke; N Gangat; R P Ketterling; R A Knudson; C A Hanson; A Bosi; A Pereira; R Manfredini; F Cervantes; G Barosi; M Cazzola; N C P Cross; A M Vannucchi; A Tefferi
Journal:  Leukemia       Date:  2014-02-19       Impact factor: 11.528

3.  Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.

Authors:  O Benjamini; M Koren-Michowitz; N Amariglio; N Kroger; A Nagler; A Shimoni
Journal:  Leukemia       Date:  2008-08-07       Impact factor: 11.528

4.  Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

Authors:  Elisa Rumi; Daniela Pietra; Cristiana Pascutto; Paola Guglielmelli; Alejandra Martínez-Trillos; Ilaria Casetti; Dolors Colomer; Lisa Pieri; Marta Pratcorona; Giada Rotunno; Emanuela Sant'Antonio; Marta Bellini; Chiara Cavalloni; Carmela Mannarelli; Chiara Milanesi; Emanuela Boveri; Virginia Ferretti; Cesare Astori; Vittorio Rosti; Francisco Cervantes; Giovanni Barosi; Alessandro M Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

Authors:  Giovanni Barosi; Gaetano Bergamaschi; Monia Marchetti; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Margherita Massa; Vittorio Rosti; Rita Campanelli; Laura Villani; Gianluca Viarengo; Elisabetta Gattoni; Giancarla Gerli; Giorgina Specchia; Carmine Tinelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2007-08-21       Impact factor: 22.113

7.  JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors.

Authors:  Alexandra Dusa; Céline Mouton; Christian Pecquet; Murielle Herman; Stefan N Constantinescu
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

8.  Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.

Authors:  H Alchalby; A Badbaran; O Bock; B Fehse; U Bacher; A R Zander; N Kröger
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

9.  Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.

Authors:  Elisa Rumi; Daniela Pietra; Paola Guglielmelli; Roberta Bordoni; Ilaria Casetti; Chiara Milanesi; Emanuela Sant'Antonio; Virginia Ferretti; Alessandro Pancrazzi; Giada Rotunno; Marco Severgnini; Alessandro Pietrelli; Cesare Astori; Elena Fugazza; Cristiana Pascutto; Emanuela Boveri; Francesco Passamonti; Gianluca De Bellis; Alessandro Vannucchi; Mario Cazzola
Journal:  Blood       Date:  2013-04-10       Impact factor: 22.113

10.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.